Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00550628 · ClinicalTrials.gov registry record
Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer
A clinical trial of Colorectal Cancer and Neoplasm of Uncertain Malignant Potential, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 8
- Enrollment target
- 1
- Study location
NCT00550628 is a study of Colorectal Cancer and Neoplasm of Uncertain Malignant Potential that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 8 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00550628, a study of Colorectal Cancer and Neoplasm of Uncertain Malignant Potential, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Diagnostic imaging procedures, such as fludeoxyglucose F 18 PET, may be effective in detecting cancer or recurrence of cancer, or premalignant polyps. PURPOSE: This clinical trial is studying fludeoxyglucose F 18-PET imaging to see how well it works in determining protein and gene expression signatures in patients with premalignant polyps or colon cancer.
Conditions Studied
Interventions
- GENETIC gene expression analysis
- GENETIC protein expression analysis
- GENETIC polymerase chain reaction
- GENETIC DNA methylation analysis
- GENETIC fluorescence in situ hybridization
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2007-09 |
| Est. Completion | 2011-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00550628
The ClinicalTrials.gov registry entry for NCT00550628 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00550628 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00550628 about?
NCT00550628 is a clinical study titled "Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer". RATIONALE: Diagnostic imaging procedures, such as fludeoxyglucose F 18 PET, may be effective in detecting cancer or recurrence of cancer, or premalignant polyps. PURPOSE: This clinical trial is studying fludeoxyglucose F 18-PET imaging to see how well it works in determining protein and gene expres...
What is the current status of trial NCT00550628?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2007-09. Estimated completion is 2011-09.
What conditions does trial NCT00550628 study?
This clinical trial studies the following conditions: Colorectal Cancer, Neoplasm of Uncertain Malignant Potential.
What interventions are being tested in trial NCT00550628?
The interventions under investigation include: gene expression analysis (GENETIC), protein expression analysis (GENETIC), polymerase chain reaction (GENETIC), DNA methylation analysis (GENETIC), fluorescence in situ hybridization (GENETIC).
Who is sponsoring clinical trial NCT00550628?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00550628 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.